Therapeutic Lymphangiogenesis Using Induced Cardiac Fibroblasts Protects the Heart From Heart Failure With Preserved Ejection Fraction Progression by Exerting Anti-Inflammatory and Antifibrotic Effects

Key Points

• Heart failure with preserved ejection fraction can be mitigated through therapeutic lymphangiogenesis, potentially halting disease progression.
• The study highlights the role of cardiac fibroblasts in exerting anti-inflammatory and antifibrotic effects during this process.
• Assessment involved understanding the remodeling and function of cardiac lymphatic vessels in heart failure progression.
• These findings may indicate a promising therapeutic avenue for heart failure treatment, but further studies are warranted.